Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations.

Autor:	Casal Moura M; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.; Faculdade de Medicina da Universidade do Porto, Departamento de Biomedicina, Porto, Portugal., Gauckler P; Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria., Anders HJ; Department of Internal Medicine IV, Hospital of the Ludwig Maximilians University, Munich, Germany., Bruchfeld A; Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.; Department of Renal Medicine, Karolinska University Hospital and CLINTEC Karolinska Institutet, Stockholm, Sweden., Fernandez-Juarez GM; Department of Nephrology, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain., Floege J; Division of Nephrology, RWTH Aachen University Hospital, Aachen, Germany., Frangou E; Department of Nephrology, Limassol General Hospital, SHSO, Cyprus; Medical School, University of Nicosia, Nicosia, Cyprus., Goumenos D; Department of Nephrology and Renal Transplantation, Patras University Hospital, Patras, Greece., Segelmark M; Division of Nephrology, Department of Clinical Sciences Lund, Lund University and Skane University Hospital, Lund, Sweden., Turkmen K; Division of Nephrology, Department of Internal Medicine, Necmettin Erbakan University, Konya, Turkey., van Kooten C; Division of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands., Tesar V; Department of Nephrology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czechia., Geetha D; Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America., Fervenza FC; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, USA., Jayne DRW; Department of Medicine, University of Cambridge, Cambridge, United Kingdom., Stevens KI; Division of Nephrology and Transplantation, Queen Elizabeth University Hospital, Glasgow, United Kingdom., Kronbichler A; Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
Jazyk:	angličtina
Zdroj:	Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2023 Oct 31; Vol. 38 (11), pp. 2637-2651.
DOI:	10.1093/ndt/gfad090
Abstrakt:	Updated guidelines on the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) were released in 2021 by the American College of Rheumatology jointly with the Vasculitis Foundation and, subsequently, in 2022 by the European Alliance of Associations for Rheumatology. In addition, in 2021, the Kidney Disease: Improving Global Outcomes had released updated recommendations on the treatment of AAV with glomerulonephritis (AAV-GN). Kidney involvement is particularly relevant in microscopic polyangiitis and granulomatosis with polyangiitis, but is less frequent in eosinophilic granulomatosis with polyangiitis. The management of AAV-GN has been a focus for drug development and change over the past 10 years. Avoidance of progression to end-stage kidney disease (ESKD) or kidney failure is one of the main unmet needs in the management of AAV, with ESKD having a major impact on morbidity, health costs and mortality risk. Relevant changes in AAV-GN management are related to remission-induction treatment of patients with severe kidney disease, the use of glucocorticoids and avacopan, and remission-maintenance treatment. All the documents provide guidance in accordance with the evidence-based standard of care available at the time of their release. With our work we aim to (i) show the progress made and identify the differences between guidelines and recommendations, (ii) discuss the supporting rationale for those, and (iii) identify gaps in knowledge that could benefit from additional research and should be revised in subsequent updates. (© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu